The FDA amended the emergency use authorizations (EUAs) for both the Pfizer–BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals, specifically, solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.   The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is schedul...